Pfizer's senior vice president to step down

William Ringo, Pfizer's Senior Vice President, Worldwide Business Development, Strategy and Innovation, will retire and be replaced by Kristin Peck.

Ringo joined Pfizer in April 2008, after retiring from Eli Lilly & Company, where over his 28-year tenure he held a number of senior positions. Between working for Lilly and Pfizer he served in leadership roles for both venture capital and biotechnology companies.

His retirement will be effective April 30, 2010, and will help his successor Kristin Peck during a transition period.

Kristin Peck has been named Senior Vice President of Worldwide Business Development, Strategy and Innovation. Most recently, she played a leadership role in the integration of Wyeth's global operations, while serving as Senior Vice President of Worldwide Strategy and Innovation.

Working closely with the business leadership, Peck will assume responsibility for business development activities, ensuring their alignment with Pfizer's strategic objectives. She will report directly to Pfizer chairman and CEO Jeff Kindler and join Pfizer's Executive Leadership Team.

Peck joined Pfizer in 2004 in the company's strategic planning organisation. Prior to Pfizer, she was a principal with the Boston Consulting Group, focusing on strategy and merger-related issues in the pharmaceutical and financial services industries, and worked in real estate financial services and private equity at Prudential and The O'Connor Group.

Peck earned her bachelor's degree from Georgetown University and her M.B.A. from Columbia Business School.